PsoriaVaTM incorporates calcipotriene 0.005%/betamethasone 0.64%) and the NexACT® technology. Pre-clinical studies have shown PsoriaVA® to deliver the same level of drugs as Taclonex with indication of superior safety profile. More
NexMed is developing RayVaTM, a topical treatment for Raynaud’s syndrome and incorporates alprostadil with the NexACT® proprietary permeation enhancer (DDAIP.HCL). More
MITI Systems has not only developed various prototypes of microneedles but also commercialized two types of polymer-based microneedle systems, Mi-Roll and Beauty Cap. More